The objective of this study was to assess the pharmacokientic parameters of regular nimodipine (Bayer  ), 30 mg, given every 6 h and nimodipine AP (nimodipine in micro particles with programmed action contained in tablets, developed by Biocontrolled-Leti Group Laboratories), 120 mg, given every 24 h. Subjects (19 healthy volunteers, five female; 14 male: age: 21 ± 0.7 years) received one formulation over 5 days. Then, after a washout period of 7 days, the other formulation was given. The analyst was blinded to the relationship in formulation received. Antecubital blood samples were taken before the first tablet was taken and after 15, 45, 60 min and 2, 4, 6, 8, 12, 13, 18 and 24 h on day 1 and five of each formulation. Nimodipine blood levels were analysed by HPLC. At steady-state regular nimodipine reached a C-max of 10.208 ± 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929
Introduction
Nimodipine is a calcium channel blocker dihydropyridine derivative with a preferential action on cerebral actions, 1,2 used in clinical practice for many years. Nimodipine has anti-vasoconstrictory and anti-ischaemic properties and is useful in cerebral vasospasm following subarachnoid haemorrhage, also is may be effective in the prevention and treatment of other neurological conditions. [3] [4] [5] [6] Nimodipine is rapidly absorbed from the gastrointestinal tract following oral administration but undergoes extensive first-pass metabolism in the liver. The oral bioavailability is reported to be about 13%. T-max occurs within 1 h. It is excreted in faeces via the bile, and in urine almost entirely as metabolites. The terminal elimination half-life is reported to be as long as 9 h but the initial decline in plasma concentration is very much more rapid, Correspondence: R Hernández Hernández, Unidad de Terapia Médica, Calle 55 entre Ave. PL Torres y Carrera 21, Edif. El Bosque, Apto. A01, Barquisimeto, Venezuela E-mail: rhernanȰcantv.net ± 0.411 ng/ml, half-life was estimated in 2.9 h. Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 ± 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 ± 0.353 ng/ml (P Ͻ 0.001). Apparent half-life was calculated in 17.8 h (P Ͻ 0.001). Area under the curve for the 24 h period was 143.76 ng/ml/min for regular nimodipine and 183.7 ng/ml/min for nimodipine AP 120 mg (P Ͻ 0.001), indicating better bioavailability. In conclusion nimodipine in AP formulation 120 mg produced similar peak plasma levels (Cmax) than regular nimodipine, but with higher trough (Cmin) values and stable plasma levels with one administration every 24 h. This formulation would be more suitable when nimodipine chronic therapy is indicated. Journal of Human Hypertension (2002) 16 (Suppl 1), S142-S144. DOI: 10.1038/sj/jhh/1001361 equivalent to a half-life of 1 to 2 h. Nimodipine is about 95% bound to plasma protein. 7 When given orally, nimodipine is usually given four times a day.
A new formulation of nimodipine in microparticles with programmed action contained in tablets, developed by Biocontrolled-Group Leti Laboratories in Caracas, Venezuela. This formulation is a released in a tablet of 120 mg, to be given once a day.
The aim of this study was to compare from the pharmacokinetic point of view the new formulation, nimodipine programmed action (nimodipine AP), given once a day, vs standard nimodipine tablets 30 mg (Bayer  ), given every 6 h.
Patients and methods
The study was carried out on healthy male and female volunteers after signing an informed consent form. A total of 19 volunteers, 14 males, five females with an average age of 22.42 years (range 18-27 years).
Volunteers were allocated at random to one of the formulations, they received the tablets over 5 days, and after a washout period of 8 days received the S143 second formulation which was also for 5 days.
Patients were in hospital on days one and five. Nimodipine AP 120 mg was given every 24 h and nimodipine regular was given every 6 h. In each case volunteers took the tablets with 250 ml of water. Antecubital blood sample was carried out at the following times: 0 (pre-treatment), 15 and 45 min, 1, 2, 4, 6, 7, 8, 12, 13, 16, 18, 24 h on the first day; and 0, 1, 2, 4, 6, 7, 8, 12, 13, 16, 18 and 24 h on the fifth day.
Blood was transported to the laboratory in a dark container using amber test tubes, blood and plasma was manipulated on red light. Storage at −20°C until assay. The analyst was blinded to the formulation received by volunteers.
Analytical methodological procedure
Nimodipine plasma level was estimated by high pressure liquid chromatography (HPLC) following the method of Qian and Gallo, 8 using a Shimadzu LC9 chromatograph with two pumps with Diode array detector and programme class LC10. Stationary phase: C8 250 × 4.6 mm, particle size 5 micron (nucleosyl/100, C8), volume of injection: 100 ml (automatic). Mobile Phase: acetonitril: water pH 2.5 with phosphoric acid (65:35), Flow rate: 2.0 ml/min. Ambient temperature of 25°C. UV detector to 241 nm. Detection limit: 0.69 ng/ml.
Calculation of pharmacokinetic parameters and statistic
Calculation of c-max, t-max, half-life and area under the curve (AUC) as pharmacokinetic parameter which was calculated by the trapezoidal rule. 
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Mean and standard error was calculated for each hour, statistical significance by pared Student's ttest (two-tailed). Table 1 shows the clinical characteristic of the volunteers included in the study.
Results
Regular nimodipine tablets given every 6 h induce a maximum concentration of 9.9916 ± 0.2191 ng/ml during the first administration, which was a slight increase to 10.208 ± 0.3167 in steady state at the fifth day of treatment. T-max was found in 1 h; estimated half-life at steady state was 171 min; with an AUC of 143.76 ng/ml/min (24 h).
Programmed action nimodipine 120 mg given once every 24 h, induce a maximum concentration of 10.27 ± 0.1659 ng /ml during the first administration, which was increased to 11.885 ± 0.4029 ng/ml not statistically different from regular nimodipine. Minimal concentration 24 h after the first dose reached 3.905 ± 0.264 ng/ml, different to 0.476 ± 0.1321 ng/ml reached with regular nimodipine 6 h after the first dosage (P Ͻ 0.001). An equivalent patron was observed on steady state with minimal concentration (trough). Estimated apparent half-life were 18 h and 33 min for the first administration and in steady state in 17 h and 52 min, being statistically different from regular nimodipine (P Ͻ 0.001). AUC in steady state was 183.7 ng/ml/min (P Ͻ 0.01) ( Table 2) .
Results can be observerd graphically in Figures 1  and 2 for regular nimodipine and nimodipine AP respectively.
Discussion
Blood pressure changes and other effects of calcium antagonists are related to plasma drug concentration, so there is a linear relationship between plasma level and their pharmacodynamic effects. 9 Plasma concentration-time profile is an appropriate predictor of the response-time profile and, correspondently, an indicator in duration of action. 10 Then clinical pharmacokinetic differences in these two formulations are of particular importance for their proper clinical use.
Regular nimodipine pharmacokinetic showed important fluctuation with every dose, and low minimum concentration after every 6 h, with low accumulation in steady state. That is why it is necessary to have frequent administration to obtain continuous clinical effect because of kinetic fluctuation, importantly clinical variability effects might be observed with this formulation.
On the other hand, nimodipine AP 120 mg, given once a day, showed similar peak plasma concentration (C-max), in 1 h (t-max), but plasma concentration was maintained steadily for the 24 h and at that time, minimum concentration was still 4.2 ng/ml significantly higher than regular nimodipine (P Ͻ 0.001), also apparent half-life was longer than regular nimodipine with an AUC higher indicating better bio-availability for nimodipine AP 120 mg.
Nimodipine AP 120 mg pharmacokinetic profile indicate steady plasma concentration over the 24 h with once a day administration, which could be clinically important to improve effectiveness and compliance, particularly in the elderly patient.
